Really promising development for IgA nephropathy patients
100 PochiniL.ScaliseM.GalluccioM.IndiveriC
Sanford M (2014) Dulaglutide: first global approval
Studies have found GLP-1RA discontinuation rates of 36%81% in the first year of treatment
Frederik Holme Fussing, Lise Witten Davodian, Danny Witten Davodian, Niklas Dyrby Johansen, Preman Kumarathurai, Daniel Modin, Stefan Sattler, Charlotte Larroud, Niels Risum, Michael Vinther, Lars Kber, Kasper Rossing, Mads Ersbll, Mikael Kjr Poulsen, Brian Bridal Lgstrup, Katja Fiedler Holm, Ketil J Haugan, Christopher Chien, Brian Claggett, Scott Solomon, Marat Fudim, Adrian Hernandez, Tarek Bekfani, Jens Brock Johansen, Jens Cosedis Nielsen, Craig M Stolen, Tor Biering-Srensen, Hemodynamic changes in response to GLP-1 treatment in ICD and CRT patients: insights from HeartLogic sensor data, European Journal of Heart Failure, 10.1093/ejhf/xuag114, (2026)
Mounjaro and Zepbound are tirzepatide